IL13 and asthma: In another study, SIRT1 activator (SIRT1720) treatment decreased the eosinophil count and IL-5 and Il-13 levels, but not IL-4 levels in the bronchoalveolar fluid and lung tissue in the ovalbumin-induced asthma mouse model [71].